AZ launches Crestor co-pay card to battle Lipitor copies

Joining the growing number of drugmakers using discount cards and coupons to retain patients, AstraZeneca ($AZN) has launched a co-pay help card for its statin drug Crestor. The cholesterol remedy isn't on the verge of going off patent, as some other meds with co-pay cards are, but Lipitor, one of its biggest rivals, is.

The new card gives insured patients an $18 co-pay for Crestor, up to $50 off their current co-pays. A patient with a $75 co-pay would pay $25 with the card, for instance, while a patient with a $60 co-pay would pay $18. Uninsured patients get a $50 discount on each monthly supply for 12 months.

The Crestor discount isn't as big as Pfizer's ($PFE) new discounts on Lipitor, which give insured patients a $4 co-pay, but Crestor isn't battling directly against pharmacies touting co-pays of $4 for patients who switch to generic copies. On the other hand, Crestor may be viewed as a statin for harder-to-treat patients, but recent study data didn't show a statistically significant superiority to Lipitor as AstraZeneca had hoped. You can be sure that analysts will be keeping a close eye on prescription numbers as soon as Lipitor loses exclusivity Nov. 30.

- read the AstraZeneca release
- get more from PharmaLetter

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.